A Novel Potential Role of Vitamin K2‑7 in Relieving Peripheral Neuropathy

Objective: To assess the efficacy, tolerability and safety of vitamin K2‑7 in patients with peripheral neuropathy (PN). Materials and Methods: This study was conducted in 100 patients with PN suffering from VBD or T2DM. Vitamin K2‑7 capsules (200 mcg) were given orally for 8 weeks followed up to the 12th week. Symptoms included tingling and numbness along with weakness, fatigue, and cramps. The intensity of the symptoms of PN was assessed on a Visual Analog Scale (VAS). Results: At baseline, the VAS score was 6–9 for VBD group and 8–10 for T2DM group. After treatment with Vitamin K2‑7 by the 12th week, VAS score had reduced to 1–2 in both groups. The decrease was statistically significant (P < 0.0001). Conclusion: For the first time, in larger sample size, it has been shown that Vitamin K2‑7, 200 mcg for 8 weeks, has a therapeutic activity for the symptoms of PN in VBD and T2DM. The reduction in symptoms was persistent in spite of de‑challenge of Vitamin K2‑7. Vitamin K2‑7 was also well tolerated by all the patients. Thus, it can be concluded that Vitamin K2‑7 has potential therapeutic effects for PN due to VBD or T2DM.